Skip to main content
. 2016 Jun 1;94(6):1348–1358. doi: 10.4269/ajtmh.15-0659

Table 1.

DENV strains, PDK passage, and viral concentration (immunofocus assay, log10 FFU/mL) of each tetravalent preparation

Virus type and PDK passage Child study Infant study
Primary F17/Pre Booster dose F17/Pre Primary F17/Pre Booster dose F17
log10 FFU/mL log10 FFU/mL
Dose 1 Dose 2* log10 FFU/mL Dose 1 Dose 2 log10 FFU/mL (at release)
DENV-1 (45AZ5) PDK 27 6.1 6.2 6.0 6.1 (1/10 dil 5.0) 6.2 (1/10 dil 4.9) 4.9
DENV-2 (S16803) PDK 50 6.2 6.4 6.1 6.3 (1/10 dil 5.3) 6.3 (1/10 dil 5.3) 5.3
DENV-3 (CH53489) PDK 20 5.1 5.0 5.0 4.8 (1/10 dil 4.1) 4.7 (1/10 dil 3.9) 4.7
DENV-4 (341750) PDK 6 6.3 6.1 6.1 6.0 (1/10 dil 5.0) 6.0 (1/10 dil 5.3) 5.0

DENV = dengue virus; dil = dilution; FFU = focus forming units; PDK = primary dog kidney.

Inactive ingredients for F17/Pre: 2.5% human serum albumin and 7.5% lactose as stabilizer, Eagle's Minimum Essential Medium (EMEM) cell culture medium, streptomycin, neomycin. Inactive ingredients for F17: cell culture medium EMEM, and stabilizers carbohydrates and amino acids for injection, streptomycin, neomycin and a proprietary stabilizer provided by GSK Vaccines.

*

Average of two independent F17/Pre retains.

Average of four independent F17/Pre retains (only for the undiluted preparations).